Improving mental health treatments through comparative effectiveness research.
There is a pressing need for comparative effectiveness research to improve mental health treatments. Although U.S. mental health spending has increased dramatically, mainly because of the rapid adoption of newer psychotropic medications, fewer than a quarter of people with serious mental illnesses receive appropriate care. Because of a general lack of information on the relative effectiveness of different treatments, payers are uncertain about the value of current spending, which in turn may deter new investments to reduce unmet need. We use several recent comparative effectiveness trials to illustrate the potential value of such research for improving practice and policy.
National Institute of Mental Health (NIMH) in Bethesda, Maryland, USA. wangphi@mail.nih.gov
Philip S
PS
Wang
Christine M
CM
Ulbricht
Michael
M
Schoenbaum
D000544:Alzheimer Disease / Q000188:drug therapy / Q000191:economics; D000928:Antidepressive Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003865:Major Depressive Disorder / Q000188:drug therapy / Q000191:economics; D016527:Drug Costs / Q000706:statistics & numerical data; D019317:Evidence-Based Medicine / Q000191:economics; D006291:Health Policy / Q000191:economics; D006801:Humans; D019458:Insurance Coverage; D007356:Insurance, Pharmaceutical Services; D001523:Mental Disorders / Q000188:drug therapy* / Q000191:economics; D011618:Psychotic Disorders / Q000188:drug therapy / Q000191:economics; D011619:Psychotropic Drugs / Q000191:economics / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012559:Schizophrenia / Q000188:drug therapy / Q000191:economics; D016896:Treatment Outcome; D014481:United States
D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D011619:Psychotropic Drugs